ERBB2 and breast carcinoma: As the anti-tumor effects of trastuzumab mainly relies on antibody-dependent cellular cytotoxicity (ADCC) effects mediated by NK cells (Musolino et al., 2022), this combination therapy might provide more effective approaches for HER2-positive breast cancer treatment.